Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension

Circulation Research

Volumn 102, Issue 6, 2008, Pages 720-728

  Letavernier, Emmanuel ^a,b,c   Perez, Joëlle ^a,b   Bellocq, Agnès ^a,b,c   Mesnard, Laurent ^a,b,c   De Castro Keller, Alexandre ^d   Haymann, Jean Philippe ^a,b,c   Baud, Laurent ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL TENON   (France)

^d CNRS   (France)

Author keywords

Angiotensin; Calpain; Nuclear factor B; Remodeling

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOTENSIN II; CALPAIN; CALPASTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERY WALL; ARTICLE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FIBROGENESIS; FIBROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; INFLAMMATION; KIDNEY ARTERY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; TRANSACTIVATION; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE; WILD TYPE; ZYMOGRAPHY;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; CALPAIN; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; FIBROSIS; GENE THERAPY; HYPERTENSION; HYPERTROPHY; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; INFUSION PUMPS, IMPLANTABLE; MICE; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; RENAL ARTERY; TIME FACTORS; VENTRICULAR REMODELING;

EID: 41449084770     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.107.160077     Document Type: Article

References (38)

1. Wong ND, Franklin SS. Epidemiology of hypertension. In Oparil S, Weber MA, eds. Hypertension. Philadelphia, Pa: Elsevier Saunders; 2005:16-28.
2. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens. 2005;14:125-131.
3. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens. 2006;24:983-991.
4. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
5. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83:731-801.
6. Zatz M, Starling A. Calpains and disease. N Engl J Med. 2005;352:2413-2423.
7. Moldoveanu T, Hosfield CM, Lim D, Elce JS, Jia Z, Davies PL. A Ca2+ switch aligns the active site of calpain. Cell. 2002;108:649-660.
8. Glading A, Bodnar RJ, Reynolds IJ, Shiraha H, Satish L, Potter DA, Blair HC, Wells A. Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol Cell Biol. 2004;24:2499-2512.
9. Lokuta MA, Nuzzi PA, Huttenlocher A. Calpain regulates neutrophil chemotaxis. Proc Natl Acad Sci U S A. 2003;100:4006-4011.
10. Kavita U, Mizel SB. Differential sensitivity of interleukin-1-alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem. 1995;270:27758-27765.
11. Bellocq A, Doublier S, Suberville S, Perez J, Escoubet B, Fouqueray B, Rodriguez Puyol D, Baud L. Somatostatin increases glucocorticoid binding and signaling in macrophages by blocking the calpain-specific cleavage of hsp 90. J Biol Chem. 1999;274:36891-36896.
12. Shumway SD, Maki M, Miyamoto S. The PEST domain of IκBα is necessary and sufficient for in vitro degradation by μ-calpain. J Biol Chem. 1999;274:30874-30881.
13. Peltier J, Bellocq A, Perez J, Doublier S, Xu Dubois Y-C, Haymann J-P, Camussi G, Baud L. Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. J Am Soc Nephrol. 2006;17:3415-3423.
14. Chansel D, Ciroldi M, Vandermeersch S, Jackson LF, Gomez AM, Henrion D, Lee DC, Coffman TM, Richard S, Dussaule J-C, Tharaux PL. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J. 2006;20:1936-1938.
15. Perez J, Viollet C, Doublier S, Videau C, Epelbaum J, Baud L. Somatostatin binds to murine macrophages through two distinct subsets of receptors. J Neuroimmunol. 2003;138:38-44.
16. Schiffrin EL. Small artery remodeling in hypertension: can it be corrected? Am J Med Sci. 2001;322:7-11.
17. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim H-S, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103:17985-17990.
18. Franco SJ, Huttenlocher A. Regulating cell migration: calpains make the cut. J Cell Sci. 2005;118:3829-3838.
19. Gross V, Obst M, Kiss E, Janke J, Mazak I, Shagdarsuren E, Müller DN, Langenickel TH, Gröne H-J, Luft FC. Cardiac hypertrophy and fibrosis in chronic L-NAME-treated AT2 receptor-deficient mice. J Hypertens. 2004;22:997-1005.
20. Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT1 receptor, transforming growth factor-β, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol. 1999;19:1843-1851.
21. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005;11:RA194-RA205.
22. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-κB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005;111:2319-2325.
23. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol. 2002;22:7603-7613.
24. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho I-C, Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 2005;115:2508-2516.
25. Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int. 2005;67:2221-2238.
26. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG, Robbins J, Lynch RA, Marreez Y, Dorn GW. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res. 2007;100:1071-1078.
27. Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S, Maki M, Saido TC. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains. Evidence from calpastatin mutant mice. J Biol Chem. 2005;280:16175-16184.
28. De Tullio R, Passalacqua M, Averna M, Salamino F, Melloni E, Pontremoli S. Changes in intracellular localization of calpastatin during calpain activation. Biochem J. 1999;343:467-472.
29. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747-803.
30. Shah BH, Catt KJ. TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. Trends Pharmacol Sci. 2006;27:235-237.
31. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature Rev Mol Cell Biol. 2006;7:589-600.
32. Burkard N, Becher J, Heindl C, Neyses L, Schuh K, Ritter O. Targeted proteolysis sustains calcineurin activation. Circulation. 2005;111:1045-1053.
33. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariety J, Michel JB. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286-294.
34. Dewitt S, Hallett M. Leukocyte membrane "expansion": a central mechanism for leukocyte extravasation. J Leukoc Biol. 2007;81:1160-1164.
35. Duffy JY, Schwartz SM, Lyons JM, Bell JH, Wagner CJ, Zingarelli B, Pearl JM. Calpain inhibition decreases endothelin-1 levels and pulmonary hypertension after cardiopulmonary bypass with deep hypothermic circulatory arrest. Crit Care Med. 2005;33:623-628.
36. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira A, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739-745.
37. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol. 2004;4:583-594.
38. Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux J-P, Baud L. Transforming growth factor-β stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol. 1995;155:2077-2084.